ACAD
ACADIA PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$27.29
−0.58%Year over year
Reported trailing growth
- Revenue
- +11.8%
- EBITDA
- -1.4%
- EBIT
- -63.5%
- EPS
- +67.9%
- Free cash flow
- -6.8%
- Operating cash flow
- +3.4%
Forward estimates
Based on analyst estimates
- Revenue
- +24.3%
- EBITDA
- +78.0%
- EPS
- -60.7%
Three-year CAGR
- Revenue
- +27.5%
- EBITDA
- +50.4%
- EBIT
- -54.6%
- Net income
- +72.7%
- EPS
- +69.3%
- Free cash flow
- -33.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026